The European signal first: regulators are moving
The clearest European development in this material is regulatory. On 24 July 2026 the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion recommending authorisation of Gilead's Trodelvy plus Keytruda in PD-(L)1-positive first-line metastatic triple-negative breast cancer.1 A CHMP opinion is a recommendation, not the final authorisation. Gilead's own release says a second first-line approval would establish Trodelvy as a backbone therapy across PD-L1 status in the European Union.1
Evandro de Azambuja said: "People with metastatic triple-negative breast cancer need effective treatment options as early as possible in the course of their disease, particularly when their tumors express PD-L1."1 That is a clinician's view, quoted in the company's release.
The same release is also the dossier's weakest link. Press-release sources like this one are rated by our system at 56% on a measured basis, meaning 56% of 4,960 checked claims held up.1 Treat company-issued announcements as company statements, not as independent findings.
Two more European threads: devices and real-world evidence
Novocure, based in Baar, Switzerland, reported second-quarter 2026 net revenues of $184 million, up 16% year over year, with 18% global active-patient growth.2 It also received a CE Mark for Optune Pax in locally advanced pancreatic cancer, with Germany the first EU market to launch. The company reports more than 280 active patients on Optune Pax as of 30 June 2026.2 Frank Leonard said: "This was our strongest quarter to date, with record net revenues and active patients on therapy."2 The numbers come from the company's own results release.
Germany features again in the third item. Kyowa Kirin International announced on 12 October 2026 the final results of the MINT study of mogamulizumab in 109 patients with mycosis fungoides and Sézary syndrome across 18 German centres. Median time to next treatment, the primary endpoint, was 14.9 months. Best overall response rate was 62.4%, and median progression-free survival was 20.2 months.3 This is real-world routine-care data rather than a controlled trial. The release also reports improved quality of life from baseline.3 It is again a company announcement, with the same 56% source-reliability rating.3
The US decisions that European investors will track
Several of the biggest near-term events are American, though they matter to anyone holding the companies involved. The FDA approved Tecentriq, and Tecentriq Hybreza, with a fluoropyrimidine and oxaliplatin for adjuvant stage III dMMR colon cancer on 9 October 2026, based on the Phase III ATOMIC study.4 Summit's application for ivonescimab, which relies on HARMONi trial results, has an FDA decision date of 14 November 2026.4 Moderna and Merck plan to present detailed intismeran results at ESMO on 24 October 2026 and to engage with regulators on potential filings.4
Talent is following the vaccine bet. Everest Medicines hired two former Moderna oncology translational leaders on 9 October 2026: Brandon Coder, formerly of cancer vaccines, and Lakshmi Srinivasan, formerly head of oncology translational medicine.4 That tells us where Everest is placing its effort. It does not tell us whether the science will work.
What a bet on a new drug type costs: Summit's verified books
Summit Therapeutics is the one company in this dossier whose financials we can state plainly, because they are checked against SEC filings. They show what a late-stage bet costs before any sales arrive.
Summit reported zero revenue in both FY2023 and FY2024.5 Its net loss was $614.9 million in FY2023, then $221.3 million in FY2024, then $1,079.6 million in FY2025.5 That last figure is more than a billion dollars. The company's cash used in operations in FY2025 was $322.9 million, so the net loss was more than three times the cash actually burned in operations.5 The dossier does not explain the gap, so we do not guess at it. Loss per share was $1.44 in FY2025, against $0.31 in FY2024 and $0.99 in FY2023.5
Operating cash flow tells the steadier story of rising spend: -$76.8 million in FY2023, -$142.1 million in FY2024 and -$322.9 million in FY2025.5 Capital expenditure is small by comparison, at $657,000 in FY2025, up from $139,000 in FY2024 and $128,000 in FY2023.5
Cash is where the funding story shows. At fiscal year-end it was $71.4 million in FY2023, $104.9 million in FY2024 and $225.3 million in FY2025.5 Quarterly figures swing widely: $297.9 million in Q2 2025, $238.6 million in Q3 2025, then $106.5 million in Q1 2026, before $419.4 million in Q2 2026.5 The dossier does not say what produced the jump. We would not infer it, but a company with no revenue and cash that moves this much is clearly dependent on outside funding and on the 14 November decision.
The AI claim: a forecast, from a source that did not pass our check
The most ambitious part of the narrative is that AI-designed biologics are the longer-term engine of oncology. The source is an MIT Technology Review piece quoting Puja Sapra, and its claims are forward-looking.6 Our measured reliability for this source is 0% of 11 checked claims holding up.6 That does not mean the statements are false. It means we could not confirm them against a source of truth, and the piece is undated in our records.
The vision is stated plainly. "Where a self-driving car uses sensors and models to navigate its environment, this system uses AI to make predictions, robotic systems to execute experiments, and instruments to generate data."6 Sapra also says: "There will be a world where models will design molecules, then scientists will work with the systems to test those molecules and put all that data together."6
The same piece is candid about what is unsolved: "One of the hardest problems in de novo design is predicting whether a computationally generated molecule will be safe in the human body."6 It also says: "With more autonomous systems, human oversight remains at the heart of this approach—ensuring explainable and ethical AI for the benefit of patients."6 For a European reader, the oversight language may matter more than the automation. Our dossier contains no EU-specific regulatory text on AI in drug design, so we do not claim one.
Our assessment is that this is a statement of intent, not a result. The dossier holds no trial outcome, approval or revenue attributed to an AI-designed molecule.
Capital in care delivery
The narrative also points to money moving into oncology care delivery: McKesson and CD&R acquiring Option Care Health, after an earlier Precision Medicine Group deal. We have no deal terms in the dossier, so we give no values. Option Care Health is headquartered in Bannockburn, IL, and is covered and rated by Zacks Equity Research.7 Zacks coverage is a rating, not a verified financial result.
One listed name is worth noting for UK and European index holders. AstraZeneca is recorded as located in the FTSE 100.7 It is linked to Rilvegostomig, Durvalumab and savolitinib, and co-develops Enhertu with Daiichi Sankyo.7 Whether your index fund owns it depends on the fund, and the dossier gives no weighting, so we cannot say how much.
What to watch
- 24 October 2026: Moderna and Merck's detailed intismeran data at ESMO, and whether they discuss filings with regulators.4
- 14 November 2026: the FDA decision date for ivonescimab. Summit's next filings will show how its cash and losses move around it.4
- The CHMP opinion for Trodelvy plus Keytruda: whether it converts to a final EU authorisation.1
- Optune Pax in Germany: whether the 280-plus patient base grows beyond the first market.2
- AI claims: look for a named molecule with human data, not further forecasts.
